Evoke Pharma Inc (EVOK) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 9 from a previous price target of $17 . FBR Capital advised their investors in a research report released on Jul 19, 2016.
Many Wall Street Analysts have commented on Evoke Pharma Inc. Evoke Pharma Inc was Downgraded by Noble Financial to ” Hold” on Jul 19, 2016. Rodman & Renshaw Downgraded Evoke Pharma Inc on Jul 18, 2016 to ” Neutral”, Price Target of the shares are set at $2.
On the company’s financial health, Evoke Pharma Inc reported $-0.45 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on May 11, 2016. Analyst had a consensus of $-0.40.
Evoke Pharma Inc closed down -7.84 points or -73.07% at $2.89 with 92,73,192 shares getting traded on Monday. Post opening the session at $2.44, the shares hit an intraday low of $2.37 and an intraday high of $3.6 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Evoke Pharma Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001 a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Companys lead product candidate EVK-001 is in late stage clinical testing. EVK-001 is a formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal yielding a variety of symptoms.